Recombinant nicotine degrading enzyme, preparation method, coding DNA and application thereof
Genetically engineered nicotine degradation enzymes to efficiently degrade nicotine in an oxygen environment, solving the problem of inefficiency of existing enzymes and broadening the scope of application, and being suitable for nicotine biorepair and pharmaceutical compound production.
Patent Information
- Application Number
- CN202310646500.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-02
- Publication Date
- 2024-12-03
AI Technical Summary
The natural electron acceptor of existing nicotine degradation enzymes is not oxygen, and the catalytic degradation of nicotine is inefficient. NicA2 relies on non-oxygen electron acceptor coenzymes, which limits its application in nicotine biorepair and the production of high-value pharmaceutical compound intermediates.
Through genetic engineering, enzyme A, which uses oxygen as the natural electron acceptor but is not nicotine, replaces its substrate-interacting amino acids, making it an enzyme with nicotine as the substrate, and replaces the spatial position of the binding amino acid sequence according to the corresponding replacement. And point mutations are performed to improve the nicotine degradation activity of the enzyme.
It has achieved efficient catalyzed nicotine degradation in an oxygen environment, and even exceeded the degradation efficiency of NicA2 with nicotine as its natural substrate, broadened the application environment of enzymes, and is suitable for nicotine biorepair and production of high-value medicinal compounds.
Smart Images

Figure CN119060977A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of enzyme engineering, and in particular to a recombinant nicotine degrading enzyme, a preparation method, a coding DNA and an application thereof. Background Art
[0002] Smoking seriously damages almost every organ in the human body, leading to cardiovascular disease, chronic obstructive pulmonary disease, lung cancer and other complex diseases. More than seven million people die from smoking each year (see the document "Cienc. Saude Coletiva 25, 4347-4350 (2020)"), far exceeding the abuse of alcohol and illegal drugs (see the document "Addiction 113, 1905-1926 (2018)"). Since nicotine is the most addictive ingredient in cigarettes and is also the cause of atherosclerosis, lung cancer, heart dysfunction, etc. (see literature "Pediatrics 139, e20163436 (2017); Cells 9, 1035 (2020)"; "J. Natl. Cancer Inst. 91, 1194-1210 (1999)"; "World J. Cardiol. 12, 192-202 (2020)"), nicotine withdrawal promotes smoking cessation treatment. Recently, a new smoking cessation method that uses enzyme metabolism to degrade nicotine in the blood circulation to prevent it from entering the brain has attracted widespread attention. The research object of this enzyme is mainly nicotine oxidoreductase NicA2 (see the literature "J.Am.Chem.Soc.137,10136-10139(2015)"; "Sci.Adv.4,eaat4751(2018)"; "BMC Biotechnol.18,46(2018)").
[0003] NicA2 is a very important enzyme in Pseudomonas putida S16. As shown below, in the nicotine pyrrolidine metabolic pathway of Pseudomonas putida S16, NicA2, Pnao (pseudo-oxidized nicotine amine oxidase), and Sapd are responsible for the conversion of the following substances: nicotine is converted into N-methyl methyl oxime (NMM), pseudo-oxidized nicotine (PN) is converted into 3-succinyl semialdehyde pyridine (SAP), and 3-succinyl semialdehyde pyridine is converted into 3-succinyl pyridine (SP), among which NMM will spontaneously hydrolyze to form PN in aqueous solution.
[0004]
[0005] Although NicA2 is the most extensively studied and efficient nicotine-degrading enzyme, its kcat is only 6.2 × 10 -3 s -1 (See the document “mBio 11, e02012-20 (2020)”). Many attempts have been made to mutate it to improve the enzyme activity, but the degree of improvement is still very limited and cannot meet actual needs (see the document “mBio 11, e02012-20 (2020)”;
[0006] "BMC Biotechnol.19,56(2019)";"Biochemistry 60,259-273(2021)"). Some studies have found that the oxidation half-reaction rate of NicA2 using oxygen as an electron acceptor is very slow, indicating that oxygen may not be its natural electron acceptor (see the literature "J.Am.Chem.Soc.137,10136-10139(2015)";"Biochemistry 60,259-273(2021)"). In fact, the natural electron acceptor of NicA2 is cytochrome c (CycN) (see the document "Nat. Chem. Biol. 17, 344-350 (2021)"), and the reliance on non-oxygen electron acceptor coenzymes limits the widespread application of NicA2 in nicotine bioremediation and production of high-value pharmaceutical compound intermediates (see the documents "Appl. Microbiol. Biot. 99, 3775-3785 (2015)"; "Appl. Microbiol. Biotechnol. 106, 889-904 (2022)"). Other nicotine oxidoreductases such as Nox, NdhAB, and VppA all rely on non-oxygen electron acceptor coenzymes and are not as active as NicA2 in catalyzing nicotine (see literature “Appl. Environ. Microbiol. 83, e01050-17 (2017)”; Appl. Environ. Microbiol. 82, 1745-1755 (2016)”; “Protein Expr. Purif. 178, 105767 (2021)”). Summary of the invention
[0007] In order to solve the problems existing in the above-mentioned prior art, the present invention provides a recombinant nicotine degrading enzyme, a preparation method, a coding DNA and an application thereof.
[0008] Specifically, the present invention provides:
[0009] (1) A recombinant nicotine degrading enzyme, characterized in that it is obtained by modifying an enzyme A that uses oxygen as a natural electron acceptor and whose natural substrate is not nicotine to use nicotine as a substrate, wherein the modification includes replacing one or more of the substrate-interacting amino acids of the enzyme A with substrate-interacting amino acids of an enzyme B whose natural substrate is nicotine, wherein the enzyme A and the enzyme B are enzymes in the nicotine metabolic pathway, belong to the same protein family, and have an amino acid sequence identity of greater than 35%.
[0010] (2) The recombinant nicotine degrading enzyme according to (1), wherein in the three-dimensional structure of the protein, there are multiple substrate-interacting amino acids of the enzyme A and the substrate-interacting amino acids of the enzyme B, which are respectively located in the substrate binding domains of the respective enzymes, and the spatial positions of the substrate-interacting amino acids of the enzyme A and the enzyme B correspond to each other, and one or more of the substrate-interacting amino acids of the enzyme A are replaced by the substrate-interacting amino acids of the enzyme B corresponding to their spatial positions.
[0011] (3) The recombinant nicotine degrading enzyme according to (1), wherein the enzyme A and the enzyme B are enzymes in the microbial nicotine pyrrolidine metabolic pathway; preferably, the microorganism is a microorganism of the genus Pseudomonas, for example, Pseudomonas putida S16, Pseudomonas plecoglossicida TND35, Pseudomonas putida JQ581, Pseudomonas sp. JY-Q.
[0012] (4) The recombinant nicotine-degrading enzyme according to any one of (1) to (3), wherein the enzyme A is Pnao, and the enzyme B is NicA2.
[0013] (5) The recombinant nicotine degrading enzyme according to (4), wherein the amino acid sequence of Pnao is as shown in SEQ ID No.: 1 or has 35% or more identity with SEQ ID No.: 1; and the amino acid sequence of NicA2 is as shown in SEQ ID No.: 2 or has 35% or more identity with SEQ ID No.: 2.
[0014] (6) The recombinant nicotine degrading enzyme according to (5), wherein the substrate-interacting amino acids of Pnao include Trp220, Gly223, Asn224, Phe388, Trp434, Gly469 and Phe470; and the substrate-interacting amino acids of NicA2 corresponding to the respective spatial positions are Tyr214, Leu217, Tyr218, Thr381, Trp427, Ala461 and Asn462.
[0015] (7) The recombinant nicotine degrading enzyme according to (5), wherein the amino acid sequence of the recombinant nicotine degrading enzyme is based on the amino acid sequence of Pnao and has the following mutations: G469A, F470N, G469A-F470N, W220Y, W220Y-G223L-N224Y, W220Y-G223L-N224Y-F388T, W220Y-G223L-N224Y-F388T-G469A-F470N, W220Y-N224Y and / or N224Y.
[0016] (8) The recombinant nicotine degrading enzyme according to any one of (1) to (3), wherein the modification further comprises, after the substrate-interacting amino acid is replaced, one or more of the substrate-interacting amino acids of the resulting enzyme are mutated to amino acids that improve the nicotine-degrading activity of the enzyme.
[0017] (9) The recombinant nicotine degrading enzyme according to (5), wherein the amino acid sequence of the recombinant nicotine degrading enzyme is based on the amino acid sequence of Pnao and has the following mutations: W220Y-N224F, W220Y-N224G, W220Y-N224H, W220Y-N224I or W220Y-N224Y.
[0018] (10) The recombinant nicotine degrading enzyme according to any one of (1) to (3), wherein the amino acid sequence of the recombinant nicotine degrading enzyme is shown in any one of SEQ ID Nos.: 3-15.
[0019] (11) The recombinant nicotine-degrading enzyme according to (4), wherein the substrate-interacting amino acid of Pnao is an amino acid that interacts with pseudo-oxidized nicotine; and the substrate-interacting amino acid of NicA2 is an amino acid that interacts with nicotine.
[0020] (12) A DNA comprising a nucleotide sequence encoding the recombinant nicotine degrading enzyme according to any one of (1) to (11).
[0021] (13) An expression vector comprising the DNA according to (12) operably linked to a promoter.
[0022] (14) A host cell, characterized in that it contains the expression vector described in (13), or a nucleotide sequence encoding the recombinant nicotine degrading enzyme described in any one of (1) to (11) is integrated into its genome.
[0023] (15) Use of the recombinant nicotine degrading enzyme according to any one of (1) to (11) in the preparation of a drug for the treatment of nicotine withdrawal.
[0024] (16) A method for preparing a recombinant nicotine-degrading enzyme, comprising genetically engineering an enzyme A that uses oxygen as a natural electron acceptor and whose natural substrate is not nicotine so that it uses nicotine as a substrate, wherein the modification comprises replacing one or more of the substrate-interacting amino acids of the enzyme A with substrate-interacting amino acids of an enzyme B whose natural substrate is nicotine, wherein the enzyme A and the enzyme B are enzymes in the nicotine metabolic pathway, belong to the same protein family, and have an amino acid sequence identity of greater than 35%.
[0025] (17) The method according to (16), wherein in the three-dimensional structure of the protein, there are multiple substrate-interacting amino acids of the enzyme A and the substrate-interacting amino acids of the enzyme B, and they are respectively located in the substrate binding domains of their respective enzymes, and the spatial positions of the substrate-interacting amino acids of the enzyme A and the enzyme B correspond to each other; wherein one or more of the substrate-interacting amino acids of the enzyme A are replaced by the substrate-interacting amino acids of the enzyme B corresponding to their spatial positions.
[0026] (18) The method according to (16), wherein the enzyme A and the enzyme B are enzymes in the microbial nicotine pyrrolidine metabolic pathway; preferably, the microorganism is a microorganism of the genus Pseudomonas, for example, Pseudomonas putida S16, Pseudomonas plecoglossicida TND35, Pseudomonas putida JQ581, Pseudomonas sp. JY-Q.
[0027] (19) The method according to any one of (16) to (18), wherein the enzyme A is Pnao, and the enzyme B is NicA2.
[0028] (20) The method according to (19), wherein the amino acid sequence of Pnao is as shown in SEQ ID No.: 1 or has a 35% or greater identity with SEQ ID No.: 1; and the amino acid sequence of NicA2 is as shown in SEQ ID No.: 2 or has a 35% or greater identity with SEQ ID No.: 2.
[0029] (21) The method according to (20), wherein the substrate-interacting amino acids of Pnao include Trp220, Gly223, Asn224, Phe388, Trp434, Gly469 and Phe470; and the substrate-interacting amino acids of NicA2 corresponding to their spatial positions are Tyr214, Leu217, Tyr218, Thr381, Trp427, Ala461 and Asn462 respectively.
[0030] (22) The method according to (20), wherein the following mutations are made to the amino acid sequence of the Pnao: G469A, F470N, G469A-F470N, W220Y, W220Y-G223L-N224Y, W220Y-G223L-N224Y-F388T, W220Y-G223L-N224Y-F388T-G469A-F470N, W220Y-N224Y and / or N224Y.
[0031] (23) A method according to any one of (16) to (18), wherein the genetic engineering modification further comprises, after the substrate-interacting amino acid is replaced, mutating one or more of the substrate-interacting amino acids of the resulting enzyme into amino acids that enhance the nicotine-degrading activity of the enzyme.
[0032] (24) The method according to (20), wherein the amino acid sequence of Pnao is subjected to the following mutations: W220Y-N224F, W220Y-N224G, W220Y-N224H, W220Y-N224I or W220Y-N224Y.
[0033] (25) The method according to (19), wherein the substrate-interacting amino acid of Pnao is an amino acid that interacts with pseudo-oxidized nicotine; and the substrate-interacting amino acid of NicA2 is an amino acid that interacts with nicotine.
[0034] Compared with the prior art, the present invention has the following advantages and positive effects:
[0035] (1) The present invention proposes for the first time to transform an enzyme in the nicotine metabolic pathway that uses oxygen as a natural electron acceptor but whose natural substrate is not nicotine into an enzyme that uses nicotine as a substrate based on the structural similarity between enzymes by replacing substrate-interacting amino acids, thereby successfully making an enzyme that cannot catalyze nicotine become able to catalyze nicotine, achieving nicotine degradation in an oxygen environment, and even obtaining a higher nicotine degradation efficiency than NicA2 that uses nicotine as a natural substrate.
[0036] (2) Based on the modification of the enzyme to use nicotine as a substrate, the present invention further performs point mutations on the key catalytic amino acids of the enzyme, thereby further improving the nicotine degradation activity of the obtained recombinant enzyme in an oxygen environment, and obtaining more highly efficient recombinant nicotine degrading enzymes.
[0037] (3) The recombinant nicotine-degrading enzyme obtained in the present invention can catalyze the degradation of nicotine in an oxygen environment, which broadens the application environment of the enzyme and increases its practicability, so that it can be widely used in nicotine bioremediation and the production of high-value pharmaceutical compound intermediates.
[0038] (4) The modification method of the recombinant nicotine degrading enzyme of the present invention is simple to operate, highly practical, and suitable for commercial and industrial applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 A photograph of the Pnao-ΔN30 protein crystals obtained in Example 2 of the present application is shown.
[0040] Figure 2 The protein purification results of the Pnao enzyme mutant constructed in Example 1 of the present application are shown; wherein M represents a molecular weight marker, and lanes 1-14 are: Pnao-W220Y-N224F, Pnao-W220Y-N224G, Pnao-W220Y-N224H, Pnao-W220Y-N224I, Pnao-W220Y-N224Y, Pnao, Pnao-W 220Y, Pnao-W220Y-G223L-N224Y, Pnao-W220Y-G223L-N224Y-F388T, Pnao-W220Y-G223L- N224Y-F388T-G469A-F470N, Pnao-N224Y, Pnao-G469A, Pnao-F470N, Pnao-G469A-F470N.
[0041] Figure 3 The three-dimensional structure analysis diagram of the Pnao enzyme is shown; wherein: Figure 3 a shows that the Pnao enzyme exists in the form of a homodimer; Figure 3b shows several groups of hydrogen bonds contained in the contact surface of the dimer: Glu134 (A) and Arg181 (B), Val132 (A) and Arg181 (B), Asn245 (A) and Asn245 (B), Arg181 (A) and Glu134 (B), His127 (A) and Glu76 (B), Glu76 (A) and Arg79 (B), Glu76 (A) and His127 (B); Figure 3 c and d show that the Pnao monomer is composed of 16 α-helices, 20 β-sheets and 36 coils, which can be divided into three parts, one part is the FAD binding domain, which is composed of a Rossmann fold, and the other two parts are substrate binding domains, which are composed of a "hot dog" fold and a helical bundle; Figure 3 e shows the "sandwich" structure composed of amino acids such as Trp434 and Phe470 in the substrate binding domain; Figure 3 f shows the Rossmann fold containing the conserved GXGXXG domain.
[0042] Figure 4 The seven amino acids in the "sandwich" structure of the substrate binding domain of the Pnao enzyme that interact with PN are shown.
[0043] Figure 5 The three-dimensional structure alignment of Pnao and NicA2 is shown.
[0044] Figure 6 The nicotine degradation activity of mutant Pnao-W220Y-N224Y (recombinant Pnao) is shown.
[0045] Figure 7 The nicotine degradation activity of the Pnao mutant (recombinant Pnao) in the preferred embodiment of the present invention is shown.
[0046] Figure 8 The nicotine degradation activities of other Pnao mutants are shown.
[0047] Fig. 9 The nicotine degradation activity of the Pnao mutant of the present invention (recombinant Pnao) in a mouse serum environment is shown.
[0048] Fig.10 The nuclear magnetic resonance spectrum of the reaction product of Pnao recombinase and nicotine in Example 5 of the present application is shown; wherein Fig.10 a shows the H NMR spectrum of the reaction product. Fig.10 b shows the carbon NMR spectrum of the reaction product. DETAILED DESCRIPTION
[0049] The following describes several preferred embodiments of the present invention with reference to the drawings in the specification, so that the technical content is clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text.
[0050] It should be understood that the above-mentioned technical features of the present invention and the technical features specifically described below (including but not limited to implementation schemes and examples) can be combined with each other in any appropriate manner to form a new or preferred technical solution, as long as there is no contradiction, and the combined technical solution can be smoothly implemented and can solve the technical problem of the present invention. The any appropriate manner shall be based on the ability to implement the technical solution of the present invention, solve the technical problem of the present invention, and achieve the corresponding technical effect.
[0051] In the present invention, "and / or" means any one or any combination of the listed items.
[0052] Unless otherwise specified, the numerical ranges in the present invention include both endpoints.
[0053] The inventors of the present invention realize that the natural electron acceptor of the existing nicotine degrading enzyme is not oxygen, and the efficiency of catalytic degradation of nicotine is low. In order to obtain an enzyme that can efficiently degrade nicotine, the inertial thinking of directly modifying the enzyme with nicotine as the substrate should be broken. Generally, protein sequences with a similarity (identity) of more than 35% can be classified into the same protein family, and the structures and functions of proteins in the same family often have similarities. Based on this, the inventors of the present invention propose that the technical means of amino acid exchange can be used to change the substrate or cofactor preference of similar enzymes (see the document "J.Am.Chem.Soc.135,10863-10869 (2013)") to transform the enzyme in the nicotine metabolic pathway that uses oxygen as a natural electron acceptor but whose natural substrate is not nicotine into one that uses nicotine as a substrate, thereby solving the problem that the natural electron acceptor of the existing nicotine degrading enzyme is not oxygen, and at the same time successfully making an enzyme that cannot catalyze nicotine become able to catalyze nicotine, thereby achieving nicotine degradation. The inventors of the present invention unexpectedly discovered that the recombinant nicotine degrading enzyme modified in this way can degrade nicotine in an oxygen environment, and even achieves a higher nicotine degradation efficiency than NicA2 which uses nicotine as a natural substrate.
[0054] Based on the above findings and inventive concepts, the present invention provides a recombinant nicotine-degrading enzyme, which is obtained by modifying an enzyme A that uses oxygen as a natural electron acceptor and whose natural substrate is not nicotine to use nicotine as a substrate, wherein the modification comprises replacing one or more of the substrate-interacting amino acids of the enzyme A with substrate-interacting amino acids of an enzyme B whose natural substrate is nicotine, wherein the enzyme A and the enzyme B are enzymes in the nicotine metabolic pathway, belong to the same protein family, and have an amino acid sequence identity greater than 35%.
[0055] In some embodiments, in the three-dimensional structure of the protein, there are multiple substrate-interacting amino acids of the enzyme A and the substrate-interacting amino acids of the enzyme B, and they are respectively located in the substrate binding domains of their respective enzymes. The spatial positions of the substrate-interacting amino acids of the enzyme A and the enzyme B correspond to each other, and one or more of the substrate-interacting amino acids of the enzyme A are replaced by the substrate-interacting amino acids of the enzyme B corresponding to their spatial positions.
[0056] In some embodiments, the enzyme A and the enzyme B are enzymes in the microbial nicotine pyrrolidine metabolic pathway. Examples of the microorganisms include microorganisms of the genus Pseudomonas, for example, Pseudomonas putida S16, Pseudomonas plecoglossicida TND35, Pseudomonas putida JQ581, Pseudomonas sp. JY-Q, etc.
[0057] Preferably, the enzyme A is Pnao, and the enzyme B is NicA2. The inventors of the present invention have found that the enzyme Pnao in the nicotine pyrrolidine metabolic pathway has a kcat of up to 0.79s when catalyzing PN with oxygen. -1 (See the document "Sci. Rep. 5, 17770 (2015)"), which is 127 times that of NicA2. The present invention has learned through phylogenetic tree analysis that the sequence similarity between Pnao and NicA2 is 39.05%, and both belong to the flavoenzyme family. Through protein three-dimensional structure analysis, it was found that the structure of Pnao is very similar to that of NicA2, and its root mean square deviation (RMSD) is only Therefore, the inventors proposed that the amino acids of Pnao and NicA2 could be exchanged so that Pnao has nicotine catalytic activity.
[0058] Therefore, in a preferred embodiment, the enzyme A is Pnao, and the modification to use nicotine as a substrate includes replacing the substrate-interacting amino acids of Pnao with the substrate-interacting amino acids of NicA2; wherein, in the three-dimensional structure of the protein, the spatial positions of the substrate-interacting amino acids of Pnao and the substrate-interacting amino acids of NicA2 correspond to each other.
[0059] Preferably, the substrate-interacting amino acid of Pnao is an amino acid that interacts with pseudo-oxidized nicotine. Preferably, the substrate-interacting amino acid of NicA2 is an amino acid that interacts with nicotine.
[0060] In a specific preferred embodiment, there are multiple substrate-interacting amino acids of Pnao and substrate-interacting amino acids of NicA2, which are respectively located in the substrate binding domains of their respective enzymes, and the amino acid sequence of the recombinant nicotine degrading enzyme has the following mutations based on the amino acid sequence of Pnao: one or more of the substrate-interacting amino acids of Pnao are mutated into substrate-interacting amino acids of NicA2 corresponding to their spatial positions.
[0061] Preferably, the amino acid sequence of Pnao is as shown in SEQ ID No.: 1 or has more than 35% identity with SEQ ID No.: 1; the nucleotide sequence is as shown in SEQ ID No.: 59 or has more than 35% identity with SEQ ID No.: 59; the amino acid sequence of NicA2 is as shown in SEQ ID No.: 2 or has more than 35% identity with SEQ ID No.: 2; the nucleotide sequence is as shown in SEQ ID No.: 60 or has more than 35% identity with SEQ ID No.: 60.
[0062] Those skilled in the art will appreciate that the amino acid sequences of enzymes (including Pnao and NicA2) in different species may be the same or different. Therefore, Pnao and NicA2 described in the present invention may also be other amino acid sequences, as long as the substrate-interacting amino acids of Pnao corresponding to each other in spatial position are replaced with the substrate-interacting amino acids of NicA2, and Pnao is catalyzed using nicotine as a substrate.
[0063] In a specific preferred embodiment, the amino acid sequence of Pnao is shown in SEQ ID No.: 1, and the amino acid sequence of NicA2 is shown in SEQ ID No.: 2. The substrate-interacting amino acids of Pnao include Trp220, Gly223, Asn224, Phe388, Trp434, Gly469 and Phe470; and the substrate-interacting amino acids of NicA2 corresponding to the spatial positions are Tyr214, Leu217, Tyr218, Thr381, Trp427, Ala461 and Asn462.
[0064] In a preferred embodiment of the present invention, the amino acid sequence of the recombinant nicotine degrading enzyme is based on the amino acid sequence of Pnao and has the following mutations: G469A, F470N, G469A-F470N, W220Y, W220Y-G223L-N224Y, W220Y-G223L-N224Y-F388T,
[0065] W220Y-G223L-N224Y-F388T-G469A-F470N, W220Y-N224Y and / or N224Y. The preferred mutations are W220Y-G223L-N224Y, W220Y-N224Y or N224Y; the more preferred mutations are W220Y-N224Y or N224Y; the most preferred mutation is W220Y-N224Y.
[0066] The inventors of the present invention further discovered that, based on modifying the enzyme A to use nicotine as a substrate, further making appropriate point mutations to the substrate-interacting amino acids of the enzyme can further improve the nicotine degradation activity of the resulting recombinant enzyme in an oxygen environment, and can obtain more highly efficient recombinant nicotine-degrading enzymes.
[0067] The suitable point mutation can be determined by saturation point mutation. The definition of saturation point mutation is known in the art, and refers to mutants in which the amino acids at the target site are replaced by other 19 natural amino acids by modifying the coding gene of the target protein. By measuring the nicotine degradation activity of each mutant, it can be determined which point mutation can improve the nicotine degradation activity of the recombinant enzyme.
[0068] Therefore, in a more preferred embodiment, the modification further comprises, after the substrate-interacting amino acid is replaced, one or more of the substrate-interacting amino acids of the resulting enzyme are mutated to amino acids that improve the nicotine-degrading activity of the enzyme.
[0069] The amino acid sequence of the recombinant nicotine degrading enzyme obtained through the above transformation steps is based on the amino acid sequence of Pnao and has the following mutations: W220Y-N224F, W220Y-N224G, W220Y-N224H, W220Y-N224I or W220Y-N224Y.
[0070] The transformation described in the present invention can be genetic engineering transformation.
[0071] Preferably, the amino acid sequence of the recombinant nicotine degrading enzyme of the present invention is shown in any one of SEQ ID No.: 3-15.
[0072] The second aspect of the present invention provides a DNA comprising a nucleotide sequence encoding the recombinant nicotine degrading enzyme according to the present invention.
[0073] The nucleotide sequences encoding the recombinant nicotine degrading enzymes whose amino acid sequences are shown in SEQ ID Nos.: 3-15 are shown in SEQ ID Nos.: 16-28.
[0074] The present invention also provides an expression vector comprising a DNA according to the present invention operatively linked to a promoter. By operatively linking a promoter sequence to the DNA, the promoter sequence can direct the expression of the corresponding protein. Generally, the expression vector used in genetic engineering techniques can be in the form of a plasmid, but the expression vector can also be in other known forms.
[0075] The present invention also provides a host cell, which contains the expression vector according to the present invention, or a nucleotide sequence encoding the recombinant nicotine degrading enzyme according to the present invention is integrated into its genome.
[0076] In the case of containing the expression vector according to the present invention, the host cell can be a cell into which the expression vector according to the present invention has been introduced. The cell can be, for example, a prokaryotic cell, which can be used, for example, to rapidly produce a large amount of the expression vector of the present invention. Host cells can also be transformed transiently or stably with the expression vector of the present invention. The expression vector can be transformed into cells by any technique known in the art, including, but not limited to, standard bacterial transformation, calcium phosphate coprecipitation, or electroporation.
[0077] The genome of the host cell may also be integrated with a nucleotide sequence encoding the recombinant nicotine degrading enzyme of the present invention.
[0078] According to the disclosure and teaching of the present invention, the recombinant nicotine degrading enzyme of the present invention can be prepared by genetic engineering or artificial synthesis.
[0079] The present invention also provides use of the recombinant nicotine degrading enzyme according to the present invention in the preparation of a drug for treating nicotine withdrawal.
[0080] Another aspect of the present invention provides a method for modifying an enzyme, that is, modifying an enzyme in the nicotine metabolic pathway that uses oxygen as a natural electron acceptor but whose natural substrate is not nicotine to use nicotine as a substrate.
[0081] Specifically, the method includes genetically engineering an enzyme A that uses oxygen as a natural electron acceptor and whose natural substrate is not nicotine so that it uses nicotine as a substrate, wherein the modification includes replacing one or more of the substrate-interacting amino acids of the enzyme A with substrate-interacting amino acids of an enzyme B whose natural substrate is nicotine, wherein the enzyme A and the enzyme B are enzymes in the nicotine metabolic pathway, belong to the same protein family, and have an amino acid sequence identity of greater than 35%.
[0082] The above method can prepare the recombinant nicotine degrading enzyme of the present invention.
[0083] Preferably, the enzyme A and the enzyme B are enzymes in the microbial nicotine pyrrolidine metabolic pathway; preferably, the microorganism is Pseudomonas putida S16.
[0084] In a preferred embodiment, in the three-dimensional structure of the protein, there are multiple substrate-interacting amino acids of the enzyme A and the substrate-interacting amino acids of the enzyme B, and they are respectively located in the substrate binding domains of their respective enzymes, and the spatial positions of the substrate-interacting amino acids of the enzyme A and the enzyme B correspond to each other in pairs; wherein one or more of the substrate-interacting amino acids of the enzyme A are replaced with substrate-interacting amino acids of the enzyme B corresponding to their spatial positions.
[0085] Preferably, the enzyme A is Pnao and the enzyme B is NicA2
[0086] Preferably, the substrate-interacting amino acid of Pnao is an amino acid that interacts with pseudo-oxidized nicotine. Preferably, the substrate-interacting amino acid of NicA2 is an amino acid that interacts with nicotine.
[0087] In a specific preferred embodiment, there are multiple substrate-interacting amino acids of Pnao and substrate-interacting amino acids of NicA2, which are respectively located in the substrate binding domains of their respective enzymes, and the modification includes replacing one or more of the substrate-interacting amino acids of Pnao with substrate-interacting amino acids of NicA2 corresponding to their spatial positions.
[0088] Preferably, the amino acid sequence of Pnao is as shown in SEQ ID No.: 1 or has more than 35% identity with SEQ ID No.: 1; the amino acid sequence of NicA2 is as shown in SEQ ID No.: 2 or has more than 35% identity with SEQ ID No.: 2.
[0089] In a specific preferred embodiment, the amino acid sequence of Pnao is shown in SEQ ID No.: 1, and the amino acid sequence of NicA2 is shown in SEQ ID No.: 2. The substrate-interacting amino acids of Pnao include Trp220, Gly223, Asn224, Phe388, Trp434, Gly469 and Phe470; and the substrate-interacting amino acids of NicA2 corresponding to the spatial positions are Tyr214, Leu217, Tyr218, Thr381, Trp427, Ala461 and Asn462.
[0090] In a preferred embodiment of the present invention, the amino acid sequence of Pnao is subjected to the following mutations: G469A, F470N, G469A-F470N, W220Y, W220Y-G223L-N224Y, W220Y-G223L-N224Y-F388T, W220Y-G223L-N224Y-F388T-G469A-F470N, W220Y-N224Y and / or N224Y. The preferred mutations are W220Y-G223L-N224Y, W220Y-N224Y or N224Y; the more preferred mutations are W220Y-N224Y or N224Y; the most preferred mutation is W220Y-N224Y.
[0091] The inventors of the present invention further discovered that, based on modifying the enzyme A to use nicotine as a substrate, further making appropriate point mutations to the substrate-interacting amino acids of the enzyme can further improve the nicotine degradation activity of the resulting recombinant enzyme in an oxygen environment, and can obtain more highly efficient recombinant nicotine-degrading enzymes.
[0092] The suitable point mutation can be determined by saturation point mutation. The definition of saturation point mutation is known in the art, and refers to mutants in which the amino acids at the target site are replaced by other 19 natural amino acids by modifying the coding gene of the target protein. By measuring the nicotine degradation activity of each mutant, it can be determined which point mutation can improve the nicotine degradation activity of the recombinant enzyme.
[0093] Therefore, in a more preferred embodiment, the genetic engineering modification further comprises, after the replacement of the substrate-interacting amino acid, mutating one or more of the substrate-interacting amino acids of the resulting enzyme into amino acids that improve the nicotine degradation activity of the enzyme.
[0094] Therefore, in other preferred embodiments, the amino acid sequence of Pnao is subjected to the following mutations: W220Y-N224F, W220Y-N224G, W220Y-N224H, W220Y-N224I or W220Y-N224Y.
[0095] In the method for modifying the enzyme or preparing the recombinant nicotine degrading enzyme of the present invention, the replacement and mutation can be achieved by conventional methods known in the art; the obtained mutant or recombinant nicotine degrading enzyme can also be cloned, expressed and purified by conventional methods known in the art.
[0096] In the present invention, the determination of the nicotine degradation activity of the enzyme can be carried out by conventional methods known in the art. For example, in a Tris-HCl buffer, the enzyme is reacted with nicotine (for example, at 30°C), and samples are taken to measure the nicotine concentration after a certain time point (for example, 8, 23, 31, 42, 57h): ethyl acetate is added and vortexed for 1min, and then the supernatant is taken after centrifugation at 13,800×g for 10min, and detected by HPLC. The detection conditions can be: Eclipse XDB-C18 as a chromatographic column (5μm, 4.6×150mm), the mobile phase is 95% ultrapure water (0.1% formic acid) and 5% methanol, and the flow rate is 0.3mL min -1 .
[0097] The present invention is further described in detail below in conjunction with the embodiments of the present invention. The following embodiments are illustrative, not restrictive, and the protection scope of the present invention should not be limited by the following embodiments. The embodiments of the present invention are implemented on the premise of the technical solution of the present invention, and detailed implementation schemes and specific operating processes are given, but the protection scope of the present invention is not limited to the following embodiments.
[0098] Example
[0099] Experimental methods (such as PCR amplification, transformation, protein purification, etc.) for which specific conditions are not specified in the examples are usually implemented according to conventional methods and conditions (such as the methods and conditions described in Sambrook et al. Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989)) or according to the conditions recommended by the manufacturer.
[0100] Unless otherwise specified, the materials, reagents, instruments, etc. used in the examples can be obtained from commercial sources.
[0101] Example 1: Construction, expression and purification of Pnao and its mutants
[0102] Using Pnao-F and Pnao-R as primers shown in Table 1 and the genome of Pseudomonas putida S16 as a template, the pnao gene was amplified by PCR to obtain the full-length gene fragment. The PCR amplification program was 95℃ 5min, [95℃ 30s, 60℃ 30s, 72℃ 2min] for 30 cycles, 72℃ 10min, and 16℃. Agarose gel electrophoresis was performed and the gel was cut and recovered using an agarose gel DNA recovery kit (Shanghai Jierui Biotechnology Co., Ltd., China). The pET-28a plasmid was then extracted using the Tiangen Rapid Plasmid Mini Extraction Kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., China), and double digested with NcoⅠ and XhoⅠ endonucleases (New England Biotechnology (Beijing) Co., Ltd., China) at 37℃, and then agarose gel electrophoresis was performed and the gel was cut and recovered using an agarose gel DNA recovery kit (Shanghai Jierui Biotechnology Co., Ltd., China). The linearized plasmid and the amplified gene fragment were ligated using the ClonExpress kit (Nanjing Novogene Biotech Co., Ltd., China) to obtain the plasmid pET-28a-pnao, which was introduced into top10 competent cells.
[0103] The mutants of Pnao were linearized with the corresponding F and R primers shown in Table 1 and the constructed pET-28a-pnao as a template to obtain the linearized plasmids of each mutant. The PCR amplification program was 95°C for 5 min, [95°C for 30 s, 60°C for 30 s, 72°C for 10 min] for 30 cycles, 72°C for 10 min, and maintained at 16°C. The circular plasmid was then digested with DpnⅠ enzyme (New England Biotechnology (Beijing) Co., Ltd., China), and the linearized plasmids of each mutant were introduced into top10 competent cells respectively. All constructed sequences were sent to Shenzhen BGI Co., Ltd. for sequencing verification.
[0104] Table 1 (where Pnao-ΔN30 refers to the truncated Pnao with 30 amino acids removed from the N-terminus)
[0105]
[0106]
[0107] Note: The underlined part is the plasmid homologous sequence, and the uppercase part is the mutation site
[0108] The constructed expression plasmid was extracted from top10 competent cells and transferred into BL21 (DE3) for protein expression. When the bacteria were cultured to OD600 of about 0.8, 0.2mM isopropyl-β-D-thiogalactoside was added for induction. After induction at 16°C overnight, the bacteria were collected and resuspended and broken with (25mM Tris-HCl pH 8.0, 300mM NaCl, 20mM imidazole), centrifuged at 4°C 13,000×g for 1h, and the supernatant was taken and Ni 2+ -NTA column purification, 70mM imidazole eluted impurities, 200mM imidazole eluted and collected target protein, ultrafiltration and concentration were performed using a 30kDa ultrafiltration tube (Millipore, USA). If it is not needed for protein crystallization analysis, it was diluted with 10 times the volume of buffer (25mM Tris-HCl pH 8.0, 200mM NaCl) and then ultrafiltration and concentration were performed. After repeating 3 times, the concentration and purity were measured and aliquoted and frozen at -80°C. If it is needed for subsequent protein crystallization analysis, it can be concentrated and then separated and purified with buffer (25mM Tris-HCl pH 8.0, 200mM NaCl) using a size exclusion chromatography column Superdex 200Increase 10 / 300GL (Cytiva Life Sciences, USA), and operated using an AKTA Purifier 900 instrument (Cytiva Life Sciences, USA). The column is flushed with buffer at a flow rate of 0.5mL / min, and the effluent is collected at a volume of 0.5mL / tube. After that, the concentration and purity are measured and the aliquots are frozen at -80°C.
[0109] The purification results are as follows Figure 2 As shown, all protein bands are single and the purity is over 95%, which can be used for subsequent enzyme activity analysis and protein crystallization.
[0110] Example 2: Analysis of Pnao protein structure
[0111] Protein crystallization analysis was performed on Pnao-ΔN30 purified by size exclusion chromatography. Protein crystallization buffer (0.2 M lithium sulfate monohydrate, 0.1 M BIS-TRIS [pH 6.5] and 25% w / v polyethylene glycol 3350) was used as the crystallization condition. 20 mg mL -1 The protein was mixed with buffer at a ratio of 1:1 (v / v) and protein crystals were obtained by hanging drop vapor free diffusion at 20°C. Figure 1 After obtaining the protein crystals, X-ray diffraction was performed using the BL19U1 beamline of the Shanghai Synchrotron Radiation Source. After collecting the diffraction data, the data were processed using HKL3000, and the structure was solved using CCP4 using the structure of NicA2 (PDB number: 7C49) as a template.
[0112] As shown in the resolved Pnao structure ( Figure 3 ), which exists in the form of homodimers in aqueous solution (such as Figure 3 a), the contact surface of the dimer contains several groups of hydrogen bonds: Glu134 (A) and Arg181 (B), Val132 (A) and Arg181 (B), Asn245 (A) and Asn245 (B), Arg181 (A) and Glu134 (B), His127 (A) and Glu76 (B), Glu76 (A) and Arg79 (B), Glu76 (A) and His127 (B) (as shown in Figure 3 b). The Pnao monomer is composed of 16 α-helices, 20 β-sheets and 36 coils, and can be divided into three parts: one part is the FAD binding domain, which is composed of a Rossmann fold and contains a conserved GXGXXG domain (such as Figure 3 f); the other two parts are the substrate binding domain, which consists of a "hot dog" fold and a helical bundle (as shown in Figure 3 c and d), a typical "sandwich" structure consisting of amino acids such as Trp434 and Phe470 was found in this binding domain (as shown in Figure 3 e), which is a conserved substrate binding domain in flavin-dependent amine oxidases and determines the substrate selection specificity.
[0113] Example 3: Pnao substrate binding pocket amino acid exchange
[0114] The natural substrate of Pnao, pseudo-oxidized nicotine (PN), was docked into the cavity where the "sandwich" domain of Pnao is located using the software AutoDock Vina. Figure 4 As shown in the figure, it can be seen that there are 7 amino acids interacting with PN, namely: Trp220, Gly223, Asn224, Phe388, Trp434, Gly469 and Phe470. Since the structure of Pnao is very similar to that of NicA2, according to the Align function of PyMol software, its root mean square deviation (RMSD) is only (like Figure 5 ). After comparing the three-dimensional structures of Pnao and NicA2, it can be seen that the seven substrate pocket amino acids in NicA2 corresponding to Pnao are Tyr214, Leu217, Tyr218, Thr381, Trp427, Ala461 and Asn462.
[0115] According to the method of Example 1, the substrate pocket amino acids of these Pnao were selectively mutated into the corresponding NicA2 amino acids, and the nicotine degradation activity and pseudo-oxidized nicotine degradation activity of wild-type Pnao, each Pnao mutant and NicA2 were tested. -1 The protein was reacted with 1 mM nicotine (or 0.5 mM pseudo-oxidized nicotine) (nicotine purchased from Sigma-Aldrich, USA, pseudo-oxidized nicotine purchased from Toronto Research Chemicals, Canada) at 30°C, and an equal volume of buffer was used to replace the protein as a blank control (BC). Samples were taken after 8, 23, 31, 42, and 57 hours to measure the concentrations of nicotine and pseudo-oxidized nicotine. Nicotine concentration detection: After adding an equal volume of ethyl acetate, vortex oscillation for 1 min, then centrifuge at 13,800×g for 10 min, take the supernatant, and detect it with HPLC1200 (Agilent, USA). The detection conditions were Eclipse XDB-C18 as the chromatographic column (5μm, 4.6×150mm), the mobile phase was 95% ultrapure water (containing 0.1% formic acid) and 5% methanol, and the flow rate was 0.3mL min -1 Detection of pseudo-oxidized nicotine concentration: 1% of the sample volume of 37% (v / v) HCl was added, and then the supernatant was taken after centrifugation at 13,800×g for 10 min. The supernatant was detected by HPLC 1200 (Agilent, USA). The detection conditions were Eclipse XDB-C18 as the chromatographic column (5μm, 4.6×150mm), 95% ultrapure water (containing 0.1% formic acid) and 5% methanol as the mobile phase, and the flow rate was 0.3mL min -1 After combined mutation, it was found that Pnao-W220Y-N224Y had the highest nicotine degradation activity. Figure 6 As shown, its nicotine degradation activity is comparable to that of NicA2, especially in the first 24 hours, when it has almost the same activity as NicA2. Later, the activity begins to decrease due to precipitation, probably because the stability of the protein is slightly lower than that of NicA2, but it is still higher than that of wild-type Pnao.
[0116] The nicotine degradation activity and pseudo-oxidized nicotine degradation activity (reaction for 24 hours) of Pnao and each mutant are summarized in Table 2.
[0117] Table 2
[0118]
[0119] Example 4: Saturation point mutation of key catalytic sites of Pnao
[0120] The present invention has been verified by single-site mutation, and N224Y has been confirmed to be the most critical mutation that enables Pnao to have nicotine degradation activity. Therefore, the single-point mutation of W220Y is retained, and Asn224 is subjected to saturation point mutation (the primers and methods used are as described in Example 1), and a total of 19 artificial enzymes are generated. The nicotine degradation enzyme activity test described in Example 3 was performed on these 19 artificial enzymes, and it was found that a total of 5 artificial enzymes had high nicotine degradation activity, such as Figure 7 As shown, within 24 hours (reaction time 10 hours), Pnao-W220Y-N224F, Pnao-W220Y-N224G, Pnao-W220Y-N224H, Pnao-W220Y-N224I, and Pnao-W220Y-N224Y were found to have nicotine degradation activity comparable to that of NicA2. Specifically, the nicotine degradation rates were 21.88%, 17.70%, 18.55%, 21.79%, and 28.28%, respectively, and the nicotine degradation rate of NicA2 was 23.80%. It can be seen that the artificial enzymes (recombinant enzymes) Pnao-W220Y-N224F, Pnao-W220Y-N224G, Pnao-W220Y-N224H, Pnao-W220Y-N224I, and Pnao-W220Y-N224Y constructed by the present invention have high nicotine degradation activity when oxygen is used as an electron acceptor, and have the potential to be developed into enzyme preparations for catalyzing nicotine reactions. The nicotine degradation activities of artificial enzymes obtained by other saturation point mutations under the same conditions are as follows: Figure 8 shown.
[0121] In order to demonstrate the feasibility of the constructed artificial enzyme of Pnao in the treatment of nicotine withdrawal, the nicotine degradation activity of the five artificial enzymes obtained above was tested in the mouse serum environment and compared with the wild-type Pnao and NicA2. The test method was consistent with the method of Example 3, except that the 25mM Tris-HCl pH 8.0 buffer was replaced with mouse serum. The results are shown in Figure 3. Fig. 9As shown, except for Pnao-W220Y-N224Y which had a lower activity (but still higher than wild-type Pnao), the other four mutants all exhibited excellent nicotine degradation activity. Within 24 hours (reaction time 10 hours), Pnao-W220Y-N224F, Pnao-W220Y-N224G, Pnao-W220Y-N224H, Pnao-W220Y-N224I and NicA2 degraded 30.39%, 26.52%, 24.60%, 19.91% and 25.83% of nicotine, respectively, which shows that the artificial enzymes (recombinant enzymes) Pnao-W220Y-N224F, Pnao-W220Y-N224G, Pnao-W220Y-N224H, Pnao-W220Y-N224I constructed by the present invention have the potential to develop drugs for treating nicotine addiction.
[0122] Example 5: Products of the reaction between Pnao artificial enzyme and nicotine
[0123] In 25 mM Tris-HCl pH 8.0 buffer, 0.2 mg mL -1 The Pnao artificial enzyme (recombinant enzyme) was reacted with 5 mM nicotine at 30 °C for 3 days, and the remaining unreacted nicotine was repeatedly extracted with an equal volume of butyl acetate, then freeze-dried and concentrated, and separated by HPLC 1200 (Agilent, USA). The separation conditions were Eclipse XDB-C18 column (5 μm, 4.6 × 250 mm), the mobile phase was 95% ultrapure water (containing 0.1% formic acid) and 5% methanol, and the flow rate was 0.3 mL min -1 , collect substances with different elution times and use Xevo G2-XS QToF (Waters, USA) to detect the purity and mass-to-nuclear ratio of the substances, collect the high-purity fraction with m / z 179, combine and freeze-concentrate, and then separate it with HPLC 1200 (Agilent, USA). The separation conditions are Eclipse XDB-C18 column (5μm, 4.6×250mm), the mobile phase is 95% ultrapure water (containing 0.05% ammonia (concentration is 25%)) and 5% methanol, and the flow rate is 0.3mL min -1 , substances with different elution times were collected and the purity and mass-to-nuclear ratio were detected by Xevo G2-XS QToF (Waters, USA), and high-purity fractions with m / z of 179 were collected, combined and freeze-dried, and finally NMR spectral data were collected at 700 MHz using AVANCE NEO (Bruker, Germany).
[0124] according to Fig.10 The NMR spectrum shown above can be used to analyze the carbon and hydrogen attribution and to determine the structural formula of the substance (i.e., the catalytic reaction product). Fig.10 As shown in a, the substance is called nicotine-1'-N-oxide, which is a degradation product of nicotine catalyzed by the recombinant enzyme of the present invention, thereby obtaining the following nicotine reaction formula:
[0125]
[0126] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. A recombinant nicotine degrading enzyme, characterized in that: The enzyme A is obtained by transforming an enzyme A which uses oxygen as a natural electron acceptor and whose natural substrate is not nicotine to use nicotine as a substrate, wherein the transformation comprises that one or more of the substrate-interacting amino acids of the enzyme A are replaced with substrate-interacting amino acids of an enzyme B whose natural substrate is nicotine, wherein the enzyme A and the enzyme B are enzymes in the nicotine metabolic pathway, belong to the same protein family, and have an amino acid sequence identity of greater than 35%.
2. The recombinant nicotine degrading enzyme according to claim 1, wherein in the three-dimensional structure of the protein, there are multiple substrate-interacting amino acids of the enzyme A and the substrate-interacting amino acids of the enzyme B, and they are respectively located in the substrate binding domains of the respective enzymes, and the spatial positions of the substrate-interacting amino acids of the enzyme A and the enzyme B correspond to each other, and one or more of the substrate-interacting amino acids of the enzyme A are replaced by the substrate-interacting amino acids of the enzyme B corresponding to their spatial positions.
3. The recombinant nicotine degrading enzyme according to claim 1, wherein the enzyme A and the enzyme B are enzymes in the microbial nicotine pyrrolidine metabolic pathway; preferably, the microorganism is a microorganism of the genus Pseudomonas, for example, Pseudomonas putida S16, Pseudomonas plecoglossicida TND35, Pseudomonas putida JQ581, Pseudomonas sp. JY-Q.
4. The recombinant nicotine degrading enzyme according to any one of claims 1 to 3, wherein the enzyme A is Pnao, and the enzyme B is NicA2.
5. The recombinant nicotine degrading enzyme according to claim 4, wherein the amino acid sequence of Pnao is as shown in SEQ ID No.: 1 or has 35% or more identity with SEQ ID No.: 1; the amino acid sequence of NicA2 is as shown in SEQ ID No.: 2 or has 35% or more identity with SEQ ID No.:
2.
6. The recombinant nicotine degrading enzyme according to claim 5, wherein the substrate-interacting amino acids of Pnao include Trp220, Gly223, Asn224, Phe388, Trp434, Gly469 and Phe470; and the substrate-interacting amino acids of NicA2 corresponding to the respective spatial positions are Tyr214, Leu217, Tyr218, Thr381, Trp427, Ala461 and Asn462.
7. The recombinant nicotine degrading enzyme according to claim 5, wherein the amino acid sequence of the recombinant nicotine degrading enzyme is based on the amino acid sequence of Pnao and has the following mutations: G469A, F470N, G469A-F470N, W220Y, W220Y-G223L-N224Y, W220Y-G223L-N224Y-F388T, W220Y-G223L-N224Y-F388T-G469A-F470N, W220Y-N224Y and / or N224Y.
8. The recombinant nicotine degrading enzyme according to any one of claims 1 to 3, wherein the modification further comprises, after the substrate-interacting amino acid is replaced, one or more of the substrate-interacting amino acids of the resulting enzyme are mutated to amino acids that improve the nicotine-degrading activity of the enzyme.
9. The recombinant nicotine degrading enzyme according to claim 5, wherein the amino acid sequence of the recombinant nicotine degrading enzyme is based on the amino acid sequence of Pnao and has the following mutations: W220Y-N224F, W220Y-N224G, W220Y-N224H, W220Y-N224I or W220Y-N224Y.
10. The recombinant nicotine degrading enzyme according to any one of claims 1 to 3, wherein the amino acid sequence of the recombinant nicotine degrading enzyme is shown in any one of SEQ ID No.: 3-15.
11. The recombinant nicotine degrading enzyme according to claim 4, wherein the substrate-interacting amino acid of Pnao is an amino acid that interacts with pseudo-oxidized nicotine; and the substrate-interacting amino acid of NicA2 is an amino acid that interacts with nicotine.
12. A DNA, characterized in that: Contains a nucleotide sequence encoding a recombinant nicotine degrading enzyme according to any one of claims 1 to 11.
13. An expression vector, characterized in that: Contains the DNA according to claim 12 operably linked to a promoter.
14. A host cell, characterized in that Contains the expression vector according to claim 13, or has a nucleotide sequence encoding the recombinant nicotine degrading enzyme according to any one of claims 1-11 integrated into its genome.
15. Use of the recombinant nicotine degrading enzyme according to any one of claims 1 to 11 in the preparation of a medicament for the treatment of nicotine withdrawal.
16. A method for preparing a recombinant nicotine-degrading enzyme, comprising genetically engineering an enzyme A that uses oxygen as a natural electron acceptor and whose natural substrate is not nicotine so that it uses nicotine as a substrate, wherein the modification comprises replacing one or more of the substrate-interacting amino acids of the enzyme A with substrate-interacting amino acids of an enzyme B whose natural substrate is nicotine, wherein the enzyme A and the enzyme B are enzymes in the nicotine metabolic pathway, belong to the same protein family, and have an amino acid sequence identity of greater than 35%.
17. The method according to claim 16, wherein in the three-dimensional structure of the protein, there are multiple substrate-interacting amino acids of the enzyme A and the substrate-interacting amino acids of the enzyme B, and they are respectively located in the substrate binding domains of their respective enzymes, and the spatial positions of the substrate-interacting amino acids of the enzyme A and the enzyme B correspond to each other; wherein one or more of the substrate-interacting amino acids of the enzyme A are replaced with the substrate-interacting amino acids of the enzyme B corresponding to their spatial positions.
18. The method according to claim 16, wherein the enzyme A and the enzyme B are enzymes in the microbial nicotine pyrrolidine metabolic pathway; preferably, the microorganism is a microorganism of the genus Pseudomonas, for example, Pseudomonas putida S16, Pseudomonas plecoglossicida TND35, Pseudomonas putida JQ581, Pseudomonas sp. JY-Q.
19. The method according to any one of claims 16-18, wherein the enzyme A is Pnao and the enzyme B is NicA2.
20. The method according to claim 19, wherein the amino acid sequence of Pnao is as shown in SEQ ID No.: 1 or has more than 35% identity with SEQ ID No.: 1; the amino acid sequence of NicA2 is as shown in SEQ ID No.: 2 or has more than 35% identity with SEQ ID No.:
2.
21. The method according to claim 20, wherein the substrate-interacting amino acids of Pnao include Trp220, Gly223, Asn224, Phe388, Trp434, Gly469 and Phe470; and the substrate-interacting amino acids of NicA2 corresponding to the spatial positions thereof are Tyr214, Leu217, Tyr218, Thr381, Trp427, Ala461 and Asn462, respectively.
22. The method according to claim 20, wherein the following mutations are made to the amino acid sequence of the Pnao: G469A, F470N, G469A-F470N, W220Y, W220Y-G223L-N224Y, W220Y-G223L-N224Y-F388T, W220Y-G223L-N224Y-F388T-G469A-F470N, W220Y-N224Y and / or N224Y.
23. The method according to any one of claims 16 to 18, wherein the genetic engineering modification further comprises, after the substrate-interacting amino acid is replaced, mutating one or more of the substrate-interacting amino acids of the resulting enzyme into amino acids that improve the nicotine-degrading activity of the enzyme.
24. The method according to claim 20, wherein the amino acid sequence of Pnao is subjected to the following mutations: W220Y-N224F, W220Y-N224G, W220Y-N224H, W220Y-N224I or W220Y-N224Y.
25. The method according to claim 19, wherein the substrate-interacting amino acid of Pnao is an amino acid that interacts with pseudo-oxidized nicotine; and the substrate-interacting amino acid of NicA2 is an amino acid that interacts with nicotine.
